AnaptysBio reports Q2 EPS ($1.50), consensus ($1.70)

Reports Q2 revenue $3.5M, consensus $3.32M. Cash, cash equivalents and investments totaled $488.7M as of June 30, 2023, compared to $584.2M as of December 31, 2022, for a decrease of $95.5M. The decrease relates primarily to cash used for the $50M stock repurchase program and operating activities. “We have made substantial operating progress including initiating a Phase 2b trial in atopic dermatitis (AD) for ANB032, our BTLA agonist, and approaching initiation of a Phase 2b trial in RA for rosnilimab, our PD-1 agonist,” said CEO Daniel Faga. “Additionally, we are excited to share that we recently completed enrollment of the GEMINI-1 Phase 3 clinical trial for imsidolimab in GPP and expect to share top-line data in Q4 2023.”